Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 20/20 | 0.65 |
| ▸ | AKR1B1 | P15121 | 8/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1249166 | 0.89 | PTGDR2 (0.81) | PTGDR2AKR1B1CYP2C9SLC6A4 | |
| SCHEMBL4250963 | 0.85 | PTGDR2 (0.62) | PTGDR2AKR1B1CYP2C9SLC6A4 | |
| SCHEMBL904388 | 0.84 | PTGDR2 (0.79) | PTGDR2AKR1B1CYP2C9SLC6A4 | |
| SCHEMBL11891652 | 0.80 | PTGDR2 (0.61) | PTGDR2AKR1B1CYP2C9SLC6A4 | |
| SCHEMBL11891659 | 0.79 | PTGDR2 (0.66) | PTGDR2AKR1B1CYP2C9SLC6A4 | |
| SCHEMBL13224608 | 0.79 | PTGDR2 (0.59) | PTGDR2AKR1B1CYP2C9SLC6A4 | |
| SCHEMBL1249444 | 0.79 | PTGDR2 (1.00) | PTGDR2AKR1B1CYP2C9SLC6A4 | |
| SCHEMBL11891653 | 0.77 | PTGDR2 (0.57) | PTGDR2AKR1B1CYP2C9SLC6A4 | |
| SCHEMBL27847238 | 0.75 | PTGDR2 (0.71) | PTGDR2AKR1B1CYP2C9SLC6A4 | |
| SCHEMBL1251032 | 0.75 | PTGDR2 (0.78) | PTGDR2AKR1B1CYP2C9SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687535-B2 | Substituted 3-sulfur indoles | ASTRAZENECA AB (SE) | 2010-03-30 | — | — | US | disclosed |
| US-20080249110-A1 | Novel Substituted 3-Sulfur Indoles | ASTRAZENECA AB (SE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249110-A1 | Novel Substituted 3-Sulfur Indoles | IDO1, IDO2, AANAT | PTGDR2 885/4885AKR1B1 2196/4885CYP2C9 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.